GWAS-to-Drug Target Discovery

Genetic Evidence Doubles Success Rate: Targets with genetic support have 2x higher probability of clinical approval (Nelson et al., Nature Genetics 2015).

Core Concepts

1. GWAS Evidence Strength

Not all genetic associations are equal. Consider:

• P-value - Statistical significance (genome-wide: p < 5×10⁻⁸)
• Effect size (beta/OR) - Magnitude of genetic effect
• Replication - Confirmed in multiple studies
• Sample size - Larger studies = more reliable
• Population diversity - Validated across ancestries

2. Druggability Criteria

A good drug target must be:

• Accessible - Protein location allows drug binding (extracellular > intracellular)
• Modality match - Target class fits drug type (GPCR → small molecule, receptor → antibody)
• Tractable - Binding pocket suitable for drug design
• Safe - Minimal off-target effects, not essential in all tissues

3. Target Prioritization Framework

GWAS Evidence (40%):

• Multiple independent SNPs = stronger signal
• Functional variants (missense > intronic)
• Tissue-specific expression matches disease

Druggability (30%):

• Known druggable protein family
• Structural data available
• Existing chemical matter

Clinical Evidence (20%):

• Prior safety data
• Validated disease models
• Biomarker availability

Commercial Factors (10%):

• Patent landscape
• Market size
• Competitive positioning

4. Drug Repurposing Logic

Repurposing works when:

1. Shared genetic architecture - Same gene implicated in multiple diseases
2. Pathway overlap - Related biological mechanisms
3. Opposite effects - Drug's mechanism counteracts disease pathology
4. Proven safety - Approved drug = de-risked

Example: Metformin (T2D drug) being tested for:

• Cancer (AMPK activation)
• Aging (mitochondrial effects)
• PCOS (insulin sensitization)

Workflow Steps

Step 1: GWAS Gene Discovery

Input: Disease/trait name (e.g., "type 2 diabetes", "Alzheimer disease")

Process:

• Query GWAS Catalog for associations
• Filter by significance threshold (p < 5×10⁻⁸)
• Map variants to genes (nearest, eQTL, fine-mapping)
• Aggregate evidence across studies

Output: List of genes with genetic support

Tools Used:

• gwas_get_associations_for_trait - Get associations by disease
• gwas_search_associations - Flexible search
• gwas_get_associations_for_snp - SNP-specific associations
• OpenTargets_search_gwas_studies_by_disease - Curated GWAS data
• OpenTargets_get_variant_credible_sets - Fine-mapped loci with L2G predictions

Step 2: Druggability Assessment

Input: Gene list from Step 1

Process:

• Check target class (GPCR, kinase, ion channel, etc.)
• Assess tractability (antibody, small molecule)
• Evaluate safety (expression profile, essentiality)
• Check for tool compounds or crystal structures

Output: Druggability score (0-1) + modality recommendations

Tools Used:

• OpenTargets_get_target_tractability_by_ensemblID - Druggability assessment
• OpenTargets_get_target_classes_by_ensemblID - Target classification
• OpenTargets_get_target_safety_profile_by_ensemblID - Safety data
• OpenTargets_get_target_genomic_location_by_ensemblID - Genomic context

Step 3: Target Prioritization

Input: Genes with GWAS + druggability data

Process:

• Calculate composite score: genetic evidence × druggability
• Rank targets by score
• Add qualitative factors (novelty, competitive landscape)
• Generate target dossiers

Output: Ranked list of drug target candidates

Scoring Formula:

Target Score = (GWAS Score × 0.4) + (Druggability × 0.3) + (Clinical Evidence × 0.2) + (Novelty × 0.1)

Step 4: Existing Drug Search

Input: Prioritized target list

Process:

• Search drug-target associations (ChEMBL, DGIdb)
• Find approved drugs, clinical candidates, tool compounds
• Get mechanism of action, indication, phase
• Check for off-label use or failed trials

Output: Drug-target pairs with development status

Tools Used:

• OpenTargets_get_associated_drugs_by_disease_efoId - Known drugs for disease
• OpenTargets_get_drug_mechanisms_of_action_by_chemblId - Drug MOA
• ChEMBL_get_target_activities - Bioactivity data
• ChEMBL_get_drug_mechanisms - Drug mechanisms
• ChEMBL_search_drugs - Drug search

Step 5: Clinical Evidence

Input: Drug candidates

Process:

• Check clinical trial history (ClinicalTrials.gov)
• Review safety profile (FDA labels, adverse events)
• Assess pharmacology (PK/PD, formulation)
• Evaluate regulatory path

Output: Clinical risk assessment

Tools Used:

• FDA_get_adverse_reactions_by_drug_name - Safety data
• FDA_get_active_ingredient_info_by_drug_name - Drug composition
• OpenTargets_get_drug_warnings_by_chemblId - Drug warnings

Step 6: Repurposing Opportunities

Input: Approved drugs + new disease associations

Process:

• Match drug targets to new disease genes
• Assess mechanistic fit (agonist vs antagonist)
• Check contraindications
• Estimate repurposing probability

Output: Repurposing candidates with rationale

Repurposing Score:

• Genetic overlap: Gene targeted by drug = gene implicated in new disease
• Clinical feasibility: Dosing, route, safety profile compatible
• Regulatory path: Faster approval (Phase II vs Phase I)

Use Cases

Use Case 1: Novel Target Discovery for Rare Disease

Scenario: Identify druggable targets for Huntington's disease

Steps:

1. Get GWAS hits for Huntington's → HTT, PDE10A, MSH3
2. Assess druggability → PDE10A (phosphodiesterase) = high
3. Find existing PDE10A inhibitors → Multiple tool compounds
4. Recommendation: Develop selective PDE10A inhibitor

Clinical Context:

• HTT (huntingtin) = difficult to drug (large, scaffold protein)
• PDE10A = modifier gene, GPCR-coupled, small molecule tractable
• Precedent: PDE5 inhibitors (sildenafil) already approved

Use Case 2: Drug Repurposing for Common Disease

Scenario: Find repurposing opportunities for Alzheimer's disease

Steps:

1. Get GWAS targets → APOE, CLU, CR1, PICALM, BIN1, TREM2
2. Find drugs targeting these → Anti-inflammatory drugs (CR1, TREM2)
3. Match approved drugs → Anakinra (IL-1R antagonist)
4. Rationale: TREM2 links inflammation to neurodegeneration

Example Output:

Repurposing Candidate: Anakinra
- Target: IL-1R → affects TREM2 pathway
- Current use: Rheumatoid arthritis (approved)
- AD rationale: 3 GWAS genes in immune pathway
- Clinical phase: Phase II trial in progress
- Safety: Known profile, subcutaneous injection

Use Case 3: Target Validation for Existing Drug Class

Scenario: Validate new diabetes targets related to GLP-1 pathway

Steps:

1. Get T2D GWAS genes → TCF7L2, PPARG, KCNJ11, GLP1R
2. GLP1R validated → Existing drug class (semaglutide, liraglutide)
3. Check related genes → GIP, GIPR (glucose-dependent insulinotropic polypeptide)
4. Outcome: Dual GLP-1/GIP agonists (tirzepatide, approved 2022)

Druggability Assessment Deep Dive

Target Classes (by Druggability)

Tier 1: High Druggability

• GPCRs (33% of approved drugs) - Extracellular binding, established chemistry
• Kinases (18% of approved drugs) - ATP-competitive inhibitors, allosteric sites
• Ion channels (15% of approved drugs) - Blocking/opening channels
• Nuclear receptors - Ligand-binding domains

Tier 2: Moderate Druggability

• Proteases - Active site inhibitors
• Phosphatases - Challenging selectivity
• Epigenetic targets - Readers, writers, erasers

Tier 3: Difficult to Drug

• Transcription factors - No obvious binding pocket
• Scaffold proteins - Large, flat surfaces
• RNA targets - Emerging modality

Modality Selection

Small Molecules:

• Target: Intracellular proteins, enzymes
• Advantages: Oral bioavailability, CNS penetration
• Disadvantages: Off-target effects, development time
• Examples: Kinase inhibitors, GPCR antagonists

Antibodies:

• Target: Extracellular proteins, receptors
• Advantages: High specificity, long half-life
• Disadvantages: Expensive, injection-only, no CNS
• Examples: PD-1 inhibitors, TNF-α blockers

Antisense/RNAi:

• Target: mRNA (any gene)
• Advantages: Sequence-specific, undruggable targets
• Disadvantages: Delivery challenges, liver-centric
• Examples: Patisiran (TTR), nusinersen (SMN)

Gene Therapy:

• Target: Genetic defects
• Advantages: One-time treatment, curative potential
• Disadvantages: Immunogenicity, manufacturing complexity
• Examples: Luxturna (RPE65), Zolgensma (SMN1)

Clinical Translation Considerations

Regulatory Requirements

IND (Investigational New Drug) Application:

• Pharmacology and toxicology
• Manufacturing information
• Clinical protocols and investigator information

Clinical Trial Phases:

• Phase I: Safety, dosing (20-100 healthy volunteers)
• Phase II: Efficacy, side effects (100-300 patients)
• Phase III: Confirmatory trials (1,000-3,000 patients)
• Phase IV: Post-market surveillance

Repurposing Advantages:

• Skip Phase I if dosing similar
• Shorter timelines (2-4 years vs 10-15)
• Lower costs ($50M vs $2B)

Success Rate Benchmarks

Traditional Drug Development (Wong et al., Biostatistics 2019):

• Phase I → II: 63%
• Phase II → III: 31%
• Phase III → Approval: 58%
• Overall: 12% (from Phase I to approval)

With Genetic Evidence (King et al., PLOS Genetics 2019):

• Phase I → Approval: 24% (2× improvement)
• Phase II → Approval: 38% vs 18% (no genetic support)

Cost and Timeline

Traditional Development:

• Pre-clinical: 3-6 years, $500M
• Clinical trials: 6-7 years, $1-1.5B
• Total: 10-15 years, $2-2.5B

Repurposing:

• Pre-clinical: 1-2 years, $50M
• Clinical trials: 2-3 years, $100-200M
• Total: 3-5 years, $150-250M

Best Practices

1. Multi-Ancestry GWAS

Why: Genetic architecture varies across populations

Approach:

• Include trans-ethnic meta-analyses
• Check replication in multiple ancestries
• Consider population-specific variants

Example: APOL1 kidney disease variants (African ancestry-specific)

2. Functional Validation

GWAS alone is not enough - need mechanistic support:

• eQTL analysis: Variant affects gene expression?
• pQTL analysis: Variant affects protein levels?
• Colocalization: GWAS + eQTL signals overlap?
• Fine-mapping: Which variant(s) are causal?

Tools for validation:

• GTEx (tissue-specific expression)
• ENCODE (regulatory elements)
• gnomAD (variant frequency, constraint)

3. Network and Pathway Analysis

Beyond Single Genes:

• Group GWAS hits by pathway (KEGG, Reactome)
• Identify druggable nodes in disease network
• Consider combination therapies

Example: Alzheimer's GWAS →

• Immune cluster (TREM2, CR1, CLU)
• Lipid cluster (APOE, ABCA7)
• Endocytosis (BIN1, PICALM)

4. Safety Liability Assessment

Red Flags:

• Essential gene (loss-of-function lethal)
• Broad expression (on-target toxicity)
• Off-target kinase panel (promiscuity)
• hERG inhibition (cardiotoxicity)
• CYP450 interactions (drug-drug interactions)

Tools:

• gnomAD pLI (intolerance to loss-of-function)
• GTEx expression (tissue specificity)
• PharmaGKB (pharmacogenomics)

5. Intellectual Property Landscape

Patent Considerations:

• Target patents (composition of matter)
• Method of use patents (indication-specific)
• Formulation patents (delivery)

Freedom to Operate:

• Existing patents on target
• Blocking patents on drug class
• Expired patents (generic opportunity)

Limitations and Caveats

GWAS Limitations

1. Association ≠ Causation

• Linkage disequilibrium = true causal variant may differ
• Pleiotropy = gene affects multiple traits
• Confounding = population stratification

Solution: Fine-mapping, functional studies, Mendelian randomization

2. Missing Heritability

• Common variants explain ~10-50% of heritability
• Rare variants, structural variants, epigenetics matter
• Gene-environment interactions

Solution: Whole-genome sequencing, family studies

3. Druggable ≠ Effective

• Can bind target ≠ modulates disease
• Right direction (agonist vs antagonist)?
• Right tissue (CNS penetration)?

Solution: Experimental validation, disease models

Target Validation Challenges

1. Mouse Models ≠ Humans

• 95% of drugs work in mice, 5% in humans
• Species differences (immune system)
• Acute models ≠ chronic disease

Solution: Human cell models (iPSCs, organoids), humanized mice

2. Genetic Perturbation ≠ Pharmacology

• Knockout = complete loss, drug = partial inhibition
• Timing matters (developmental vs adult)
• Compensation in knockout

Solution: Inducible knockouts, tool compounds

3. Efficacy ≠ Safety

• On-target toxicity (essential gene)
• Off-target effects (selectivity)
• Dose-limiting side effects

Solution: Therapeutic index assessment, biomarkers

Ethical and Regulatory Considerations

Human Genetics Research

Informed Consent:

• Secondary use of GWAS data
• Return of results policies
• Privacy protections (de-identification)

Equity:

• Most GWAS = European ancestry (78%)
• Risk: Drugs may not work equally across populations
• Solution: Diversify GWAS cohorts

Clinical Trials

Study Design:

• Stratification by genetics (precision medicine)
• Adaptive trials (basket, umbrella designs)
• Real-world evidence (pragmatic trials)

Patient Selection:

• Enrichment by genotype (higher response rate)
• Ethics of genetic testing for trial entry
• Cost-effectiveness of stratified medicine

Regulatory Pathways

FDA Breakthrough Therapy:

• Substantial improvement over existing
• Expedited review (6 months vs 10 months)
• Examples: CAR-T therapies, gene therapies

Accelerated Approval:

• Based on surrogate endpoints
• Post-market confirmation required
• Risk: Approval withdrawal if confirmatory fails

Resources and References

Databases

GWAS:

• GWAS Catalog - Curated GWAS results
• Open Targets Genetics - Fine-mapping, L2G
• PhenoScanner - Cross-trait lookups

Drugs:

• ChEMBL - Bioactivity database
• DrugBank - Comprehensive drug information
• DGIdb - Drug-gene interactions

Targets:

• Open Targets Platform - Target-disease associations
• PHAROS - Target development level (Tdark to Tclin)

Clinical:

• ClinicalTrials.gov - Clinical trial registry
• FDA Labels - Drug labeling information

Key Literature

Genetic Evidence for Drug Targets:

• Nelson et al. (2015) Nature Genetics - Genetic support doubles clinical success
• King et al. (2019) PLOS Genetics - Systematic analysis of target success

GWAS to Function:

• Visscher et al. (2017) American Journal of Human Genetics - 10 years of GWAS
• Claussnitzer et al. (2020) Nature Reviews Genetics - From GWAS to biology

Drug Repurposing:

• Pushpakom et al. (2019) Nature Reviews Drug Discovery - Repurposing opportunities
• Shameer et al. (2018) Nature Biotechnology - Computational repurposing

Success Stories:

• Plenge et al. (2013) Nature Reviews Drug Discovery - IL-6R to tocilizumab
• Cohen et al. (2006) Science - PCSK9 to evolocumab

Disclaimer

For Research Purposes Only

This skill is designed for:

• Target discovery and validation
• Drug repurposing hypothesis generation
• Preclinical research planning

NOT for:

• Clinical decision-making
• Patient treatment recommendations
• Regulatory submissions (without validation)

Important Notes:

• All targets require experimental validation
• GWAS evidence is correlational, not causal
• Regulatory approval requires extensive preclinical and clinical data
• Consult domain experts (geneticists, pharmacologists, clinicians)

Liability: The authors assume no liability for actions taken based on this analysis. All therapeutic development requires rigorous validation and regulatory oversight.

Version History

• v1.0.0 (2026-02-13): Initial release with GWAS-to-drug workflow
  • Support for GWAS Catalog, Open Targets, ChEMBL, FDA tools
  • Target discovery, druggability assessment, repurposing identification
  • Comprehensive documentation with examples

Future Enhancements

Planned Features:

• Integration with UK Biobank for larger-scale GWAS
• PheWAS (phenome-wide association studies) for pleiotropic effects
• Mendelian randomization for causal inference
• Network-based target prioritization
• AI-powered structure-activity relationship (SAR) prediction
• Clinical trial matching for repurposing candidates

Tool Additions:

• PDB (Protein Data Bank) for structural druggability
• STRING for protein-protein interaction networks
• DisGeNET for disease-gene associations
• ClinVar for pathogenic variant interpretation

Contact

For questions, issues, or contributions:

• GitHub: [ToolUniverse Repository]
• Documentation: [skills/tooluniverse-gwas-drug-discovery/]
• Email: [email protected]